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Abstract 
Background: The analysis of mobile health (mHealth) data has generated innovative insights into improving allergic 
rhinitis control, but additive information is needed. A cross‑sectional real‑world observational study was undertaken 
in 17 European countries during and outside the estimated pollen season. The aim was to collect novel information 
including the phenotypic characteristics of the users.
Methods: The Allergy Diary–MASK‑air–mobile phone app, freely available via Google Play and App, was used to 
collect the data of daily visual analogue scales (VASs) for overall allergic symptoms and medication use. Fluticasone 
Furoate (FF), Mometasone Furoate (MF), Azelastine Fluticasone Proprionate combination (MPAzeFlu) and eight oral 
H1‑antihistamines were studied. Phenotypic characteristics were recorded at entry. The ARIA severity score was 
derived from entry data. This was an a priori planned analysis.
Results: 9037 users filled in 70,286 days of VAS in 2016, 2017 and 2018. The ARIA severity score was lower outside 
than during the pollen season. Severity was similar for all treatment groups during the pollen season, and lower in 
the MPAzeFlu group outside the pollen season. Days with MPAzeFlu had lower VAS levels and a higher frequency of 
monotherapy than the other treatments during the season. Outside the season, days with MPAzeFlu also had a higher 
frequency of monotherapy. The number of reported days was significantly higher with MPAzeFlu during and outside 
the season than with MF, FF or oral H1‑antihistamines.
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Background
Observationl real-life studies using mobile technology 
can complement randomized control trials (RCTs) and 
improve the positioning of allergic rhinitis (AR) medi-
cations in care pathways. MASK-air (Mobile Airways 
Sentinel NetworK) is an information and communica-
tion technology (ICT) system which is centred around 
the patient. It uses a treatment scroll list which includes 
all medications customized for each country as well as 
a visual analogue scale (VAS) to assess rhinitis control 
[1–3]. Two studies in over 9000 users and 22 countries 
enabled differentiation between AR treatments [3, 4] and 
showed that the assessment of daily data was useful in 
the understanding of treatment patterns. Most allergic 
rhinitis (AR) patients use on-demand treatment when 
they are suboptimally controlled. As in resistant hyper-
tension, defined by the number of medications used to 
control the disease [5], many patients have a worse con-
trol when increasing their medications [3, 4]. Differences 
in efficacy between intranasal corticosteroids (INCS) and 
intra-nasal MPAzeFlu were observed [3, 4]. These studies 
were carried out across the year and it is possible that the 
results differ during and outside the pollen season as the 
allergen exposure differs and the disease may not be the 
same in terms of phenotypes [6, 7] and costs [8]. Another 
MASK study in 12,143 users and 23 countries found that 
very few patients reporting data for several days were 
adherent [9]. These studies combined propose novel con-
cepts for AR treatment. However, they failed to show cer-
tain key facts including the phenotypic characteristics of 
the patients at entry and whether the conclusions raised 
are applicable during and outside the pollen season.
The present analysis is a follow-up of previous MASK 
studies attempting to answer unresolved questions to 
provide novel real-world data information. A new cross-
sectional observational study undertaken in 9037 users 
and 17 European countries examined AR treatments dur-
ing and outside the pollen seasons (2016, 2017 and 2018). 
Two-thirds of the participants were already enrolled in 
previous studies, but analyses differed. The aim of the 
study was (i) to assess the participants’ characteristics to 
better assess their phenotypes, (ii) to study whether the 
same trends in treatment efficacy are found during high 
and low allergen loads, assessed according to a recent 
study [10], and (iii) to investigate whether the trends in 
treatment efficacy were associated with the severity of 
the disease at entry. The study was focussed on the most 
commonly used intra-nasal medications containing corti-
costeroids: Fluticasone Furoate (FF), Mometasone Furo-
ate (MF) and MPAzeFlu [3, 4], reported as monotherapy 
or co-medication [3, 4, 11]. It also focussed on the most 
common oral  H1-antihistamines (OAH) reported as 
monotherapy: Bilastine, Cetirizine (CET), Desloratadine 
(DL), Ebastine, Fexofenadine (FEXO), Levocetirizine 
(LEVOCET), Loratadine (Lora) and Rupatadine. We did 
not study OAH reported as co-medication, as they are 
usually associated with INCS. Untreated days were used 
as a control group.
Methods
Users
All users of the app in Europe in 2016, 2017 and 2018 
were included with no exclusion criteria and according to 
methods previously described [4, 11] .
Setting
Users from 17 countries filled in the Allergy Diary 
(Tables  1 and 2).
Ethics and privacy
The Allergy Diary is CE1 registered. By using k-ano-
nymity, the data were all anonymized including the data 
related to geolocalization [12]. MASK-air® is in line 
with the General Data Protection Regulation (GDPR) 
EU Directive 95/46/EC [13]. Independent Review Board 
approval was not required since the study is observa-
tional and users agree to having their data analysed 
(terms of use).
Allergy diary (MASK‑air®)
Geolocalized users self-assessed their daily symptom 
control using the touchscreen functionality on their 
smart phone to click on a VAS score (ranging from 0 
to 100) for overall symptoms (global VAS). Some users 
reported VAS scores more than once a day. In previous 
studies, we found that the highest reported value should 
be used and we followed this. According to previous stud-
ies, severity was defined as “no symptoms” (VAS ranging 
from 0 to 20), “mild” (20 to 50) and “severe” (≥ 50) [1, 14].
Users input their daily medications using a scroll list 
which contains all country-specific OTC and prescribed 
medications available for each country. Both the active 
ingredient and the marketed OTC and prescribed medi-
cations are listed. The list has been populated using IMS 
Conclusions: This study shows that the overall efficacy of treatments is similar during and outside the pollen season 
and indicates that medications are similarly effective during the year.
Keywords: Allergic rhinitis, Anti‑histamines, Corticosteroids, ICT, Mobile health, MASK, Treatment
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data. Days with or without treatment were reported by 
users. The present study is another MASK study. Some 
of the raw data used in the other papers (up to December 
2017) were used in this study [4]. However, new data have 
been included, many of the analyses are different and 
estimated allergen exposure was not previously analyzed.
Time of the study
We did not study all individual locations as only around 
60% of subjects agreed to be geolocalized and we knew 
only the country of origin in the non-geolocalized users. 
We therefore estimated the pollen season for each coun-
try using Google Trends and terms previously defined 
[15, 16]. We found that overall, across Europe, the season 
covered March 15 to the end of June. We have published 
a series of papers on Google Trends to better understand 
pollen seasons and the drawbacks of the method [15, 
17–23]. They can roughly appreciate the season. On the 
other hand, pollen counts cannot be used on a daily basis. 
Moreover, they are not available for all locations. Thus, 
they cannot be used in the current study. To assess the 
pollen season precisely, personal samplers should be used 
but it would be impossible to use them in thousands of 
patients and, due to privacy, they cannot be used in this 
study.
We estimated the period outside the pollen season 
as August 1 to December 31. We therefore avoided the 
early tree pollen season (January-March) and excluded 
days recorded in Austria and France between August 1 
and September 15 to avoid the ragweed pollen season. 
In a recent paper, the same approach was used to assess 
impact of pollution on the pollen season [24].
Selection of medications
The International Nonproprietary Names (INN) classifi-
cation was used for drug nomenclature [25]. Monother-
apy was defined as days when only one single medication 
for rhinitis was reported. MPAzeFlu contains two drugs 
but, being a fixed combination, it was considered as mon-
otherapy. Co-medication was defined as days with two or 
more medications for rhinitis. Asthma medications were 
not considered in co-medication.
Characteristics at entry
According to a previous study, we considered AR symp-
toms recorded upon the first use of the app (rhinor-
rhea, sneezing, nasal congestion, nasal itching, ocular 
symptoms) [26]. On the same day (i.e. at entry), we 
assessed the ARIA severity score calculated by using the 
four questions regarding impact on sleep, daily activi-
ties, work/school attendance, and bothersome symp-
toms. Each of these four items was ascribed a score of 
1 (“Yes”) or 0 (“No”). The total ARIA score ranged from 
Table 1 Country and  number of  users recording Visual 
Analogue Scale score using MASK-air® during  the  pollen 
season
Country VAS measurements (days)
1 2 to 7 8 to 14  > 14 Total
Austria 144 (57%) 74 14 22 254
Belgium 50 (57%) 26 6 6 88
Czech Republic 9 (29%) 10 2 10 31
Denmark 20 (38%) 18 5 10 53
Finland 109 (43%) 90 20 32 251
France 378 (56%) 222 28 43 671
Germany 205 (38%) 141 54 141 541
Greece 22 (17%) 33 21 53 129
Italy 408 (45%) 294 67 132 901
Lithuania 64 (23%) 82 37 98 281
Netherlands 341 (46%) 276 58 67 742
Poland 251 (45%) 189 35 84 559
Portugal 549 (49%) 439 60 82 1130
Spain 102 (32%) 98 39 78 317
Sweden 16 (40%) 13 6 5 40
Switzerland 428 (61%) 200 27 42 697
UK 101 (40%) 95 39 19 254
Total 3197 (46%) 2300 (33%) 518 (8%) 924 (13%) 6939
Table 2 Country and  number of  users recording Visual 
Analogue Scale score using MASK-air® outside  the  pollen 
season
Country VAS measurements (days)
1 2 to 7 8 to 14  > 14 Total
Austria 33 (54%) 15 3 10 61
Belgium 24 (46%) 17 4 7 52
Czech Republic 6 (60%) 0 0 4 10
Denmark 18 (55%) 13 0 2 33
Finland 26 (56%) 18 1 1 46
France 45 (48%) 34 4 10 93
Germany 90 (60%) 37 8 15 150
Greece 38 (31%) 35 15 35 123
Italy 139 (36%) 101 32 109 381
Lithuania 35 (20%) 51 22 67 175
Netherlands 64 (61%) 25 9 7 105
Poland 105 (58%) 53 10 14 182
Portugal 114 (50%) 76 20 19 229
Spain 95 (39%) 79 28 44 246
Sweden 26 (51%) 20 3 2 51
Switzerland 20 (71%) 29 0 0 28
UK 71 (53%) 42 9 11 133
Total 949 (45%) 624 (30%) 168 (8%) 357 (17%) 2098
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0 (no impairment) to 4 (severe impairment). This score 
was found to correlate with EQ-5D and WPAI-AS using 
MASK [27] and was used in an epidemiological study 
[28].
Size of the study
In this study, all registered users were included to obtain 
the best possible estimates for the specified time win-
dow. From previous studies, the   numbers tested largely 
exceed those needed to find significant differences in the 
full set analysis [4].
Stratification of the users
The stratification was determined by season of enrolment 
(i.e. during or outside the pollen season).
Statistical methods
A non-Gaussian distribution was found for the data. 
Non-parametric tests and medians (and percentiles) 
were used.
Analysis of the data
All analyses were conducted separately for users who 
were enrolled and used the app (i) during the pollen sea-
son (discarding days reported outside the pollen season 
by those users) and (ii) outside the pollen season (dis-
carding days reported during the pollen season by those 
users).
All analyses were conducted by comparing the days 
when app users reported the use of INCS treatment (FF, 
MPAzeFlu, MF), the use of OAH in monotherapy, and 
the days when users did not report any treatment (days 
with other treatment were excluded from the analyses).
According to the treatment (FF, MPAzeFlu, MF, OAH 
in monotherapy or no treatment) reported at entry day 
(thereafter called Day 1), we compared (i) character-
istics reported by the user on Day 1 (i.e. AR symptoms, 
impact of symptoms and ARIA score), (ii) the distribu-
tion of global VAS reported by the users on Day 1, and 
(iii) the proportion of monotherapy versus comedication 
reported for the use of that treatment.
The comparison analyses described in (ii) and (iii) were 
also conducted on all the days of App use, i.e. for all the 
days of App use, we compared the distribution of global 
VAS, as well as the proportion of monotherapy versus 
comedication, according to the treatment reported on 
that day.
Finally, for each treatment, we compared the average 
number of days of treatment reported per user, estimated 
by dividing the total number of days for which the use of 
a medication was reported by the total number of users 
reporting that medication at least once.
To investigate the consistency of our results during and 
outside the pollen season, we compared characteristics at 
entry between during and outside the pollen season.
The ARIA score on Day 1 (ranging from 0 to 4) was 
considered either as a continuous or a categorical vari-
able. Global VAS was considered either as a continu-
ous, or a categorical variable - using three cutoffs: 
VAS < 20/100 (controlled days), VAS 20-49 (days with 
moderate control), VAS ≥ 50 (days with poor control) [4, 
11]. Chi square tests were used to compare the distribu-
tion of categorical variables (i.e. symptoms and impact of 
symptoms on Day 1, ARIA score on Day 1, global VAS 
categories). Kruskal–Wallis tests were used to compare 




The study included 9037 users (i.e. 6939 who started 
to use the app during the pollen season and 2098 who 
started outside the season). Roughly 5% of users did 
not report their age or reported an age of below 10. 
Users ranged from zero to 91  years-old (mean, SD: 
33.5 ± 15.5 years). There were 53.5% of women and 46.5% 
of men.
A total of 211,003  days were recorded between 2016 
and 2018. Duplicates or multiplicates for the same day 
were found in 4397  days. 49,566  days were recorded 
by the 6939 users during the pollen season. There were 
23,377 (54.4%) days without treatment and 19,568 (45.6%) 
days with the targetted INCS or OAH. 20,720 days were 
recorded by the 2098 users outside the pollen season. 
There were 13,130 (69.5%) days without treatment and 
5756 (30.5%) days with treatment (Fig. 1).
Characteristics on Day 1
Characteristics on Day 1 are given in Tables 3 and 4 for 
the pollen season and in Tables  3 and 5 for outside the 
pollen season.
During the pollen season (Table 4), 69 to 78% of users 
reported rhinorrhoea on Day 1. Other nasal symptoms 
were reported in 55 to 87% of users, and ocular symp-
toms in 42 to 74%. Most users reported bothersome 
symptoms (74–78%). Impact on sleep, daily activities 
and work/school attendance was reported in 27–50% of 
users. The ARIA score was similar in all five groups of 
users.
Outside the pollen season (Table  5), 55 to 72% of 
users reported rhinorrhoea on Day 1. Other nasal 
symptoms were reported in 49 to 84% of users and ocu-
lar symptoms in 21 to 62%. Most users reported both-
ersome symptoms (55–84%). Impact on sleep, daily 
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activities and work/school attendance was reported in 
24 to 47% of users. The use of MPAzeFlu on Day 1 was 
significantly associated with fewer symptoms, com-
pared to the use of FF or MF. App users who reported 
the use of MPAzeFlu on Day 1 were less likely to report 
a severe impact of symptoms, compared to users of FF 
or MF on Day 1. However, the difference was only bor-
derline significant.
Significantly more symptoms on Day 1 were reported 
during the pollen season than outside the pollen sea-
son, and the ARIA severity score was significantly 
higher outside the pollen season. Similar trends were 
found when restricting the population to users not 
reporting treatment on Day 1 (results not shown).
Treatment efficacy
During the pollen season, on Day 1, VAS levels were 
reported by 3736 users without treatment, 1414 users 
with OAH in monotherapy and 841 users with INCS 
treatment (Table  4). No statistically significant differ-
ence in VAS levels was observed between INCS treat-
ments on Day 1. When all VAS days were studied, we 
observed significantly lower VAS levels in MPAze-
Flu days compared to other INCS (FF or MF) days 
(p = 0.0001, Table 4).
Outside the pollen season, on Day 1, VAS levels were 
reported by 1299 users without treatment, 275 users 
with OAH in monotherapy and 274 users with INCS 
treatment (Table  5). No statistically significant differ-
ence in VAS levels was observed between INCS treat-
ments on Day 1. When all VAS days were studied, we 
observed non-significant differences between MPAze-
Flu use compared to other INCS use or OAH.
Monotherapy versus co‑medication according to INCS use
During the pollen season, monotherapy was signifi-
cantly more reported in users who reported the use of 
MPAzeFlu on Day 1 (44%) compared to app users who 
Fig. 1 Flow chart of the study population
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reported the use of FF or MF on Day 1 (i.e. between 30 
and 35%) (p < 0.01). Similar results were found when all 
VAS days were studied (p < 0.001) (Fig. 2).
Outside the pollen season, monotherapy was signifi-
cantly more reported in users who reported the use 
of MPAzeFlu on Day 1 (71%) compared to those who 
reported the use of FF or MF on Day 1 (40 to 50%) 
(p < 0.001). Similar results were found when all VAS 
days were studied (p < 0.001) (Fig. 2).
Number of days with treatment
In untreated users, the estimated average number of 
days of reporting per user increased from 5.1  (during 
pollen season) to 8.5 (outside). Both during and out-
side the pollen season, there was a similar trend of days 
reported from OAH, FF, MF to MPAzeFlu (Tables 4 and 
5). The average number of days of reporting per user 
was low for OAH (4.5  days) and increased to around 
10  days for MPAzeFlu (during and outside pollen 
season).
Discussion
Two MASK studies [4, 11] have shown that, in real life, 
the assessment of days can provide (i) information on 
patients’ treatment (ii) novel insight into the behaviour 
of AR patients towards treatment and (iii) novel con-
cepts for change management of AR [29]. In the present 
study (Table 3), we show that the ARIA severity score is 
(i) lower outside than during the pollen season (ii) similar 
for all INCS treatment groups on Day 1 during the pol-
len season and (iii) lower in the MPAzeFlu group than in 
the MF and FF groups outside the pollen season. We also 
show that MPAzeFlu might be more effective than FF or 
MF in the pollen season (lower VAS levels are reported 
in days with MPAzeFlu treatment, and MPAzeFlu is 
more frequently used as monotherapy) as well as outside 
the pollen season (more frequent use of monotherapy). 
Finally, the number of days of reported treatment per 
user increased from OAH to MPAzeFlu (Table 6).
Strengths and limitations
Strengths and limitations of MASK have previously 
been reported [11]. As for all studies using participatory 
data, potential biases include (i) the likelihood of sam-
pling bias being present (ii) the lack of generalizability 
Table 3 Comparison of characteristics and VAS levels at entry recorded during and outside the pollen season
FF Fluticasone Furoate, FP Fluticasone Propionate, MF Mometasone Furoate, MPAzeFlu Azelastine-Fluticasone Propionate
*Chi square tests were used for categorical variables (i.e. baseline symptoms and impact of symptoms, ARIA score); Kruskal–Wallis tests were used for continuous 
variables (i.e. ARIA score)
p25:  25th percentile; p75:  75th percentile
During pollen season 
(n = 6939)




Itchy nose (%) 73 66 <0.001
Sneezing (%) 61 55 <0.001
Congestion (%) 69 65 0.001
Red eyes (%) 46 37 <0.001
Itchy eyes (%) 68 53 <0.001
Watery eyes (%) 47 38 <0.001
Impact of symptoms Day 1
Sleep (%) 38 35 0.06
Daily activities (%) 45 39 <0.001
Work/school (%) 30 26 <0.001
Bothersome (%) 76 68 <0.001
ARIA score (%) 0 14 20
1 30 32
2 25 21 <0.001
3 18 16
4 14 12
Median [p25‑p75] 2 [1–3] 1 [1–3] <0.001
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of the study that was found, as bothersome symptoms 
are present in around 80% of users, indicating that most 
users have a moderate to severe disease, and (iii) out-
come misclassification that cannot be assessed. Data 
obtained with an app are not representative of the gen-
eral population.
In the previous MASK studies, there was very lit-
tle information on patient characteristics. In the pre-
sent study, we examined characteristics at entry in more 
detail.
As in other studies [4, 11], we used days in a cross-
sectional analysis because there is no clear pattern of 
Table 4 Results for all participants recruited during the pollen season
FF Fluticasone Furoate, MF Mometasone Furoate, MPAzeFlu Azelastine-Fluticasone Propionate
* Comparing MPAzeFlu versus FF or MF. Chi square tests were used for categorical variables (i.e. symptoms and impact of symptoms, ARIA score, global VAS 
categories); Kruskal–Wallis tests were used for continuous variables (i.e. ARIA score, global VAS)
± Estimated by dividing the total number of days for which the use of a medication was reported by the total number of users reporting that medication
p25:  25th percentile; p75: 75th percentile
Treatment days No treatment days P value*
FF MPAzeFlu MF OAH mono
N users Day 1 331 (5.5%) 159 (2.7%) 351 (5.9%) 1414 (23.6%) 3736 (62.4%)
Symptoms Day 1
 Runny nose (%) 69 74 75 78 69 0.77
 Itchy nose (%) 68 55 65 67 57 0.006
 Sneezing (%) 79 73 76 87 77 0.20
 Nasal congestion (%) 75 74 79 71 64 0.37
 Red eyes (%) 50 44 42 52 42 0.56
 Itchy eyes (%) 70 64 68 74 64 0.22
 Watery eyes (%) 48 42 45 54 43 0.29
Impact of symptoms Day 1
 Sleep (%) 44 44 47 41 32 0.70
 Daily activities (%) 41 50 50 49 41 0.36
 Work/school (%) 31 42 33 33 27 0.02
 Bothersome (%) 76 77 77 78 74 0.94
ARIA score (%)
 0 11 11 12 11 16
 1 29 26 23 28 32
 2 30 24 27 26 24 0.08
 3 19 16 23 21 16
 4 12 23 16 15 12
 Median [p25‑75] 2 [1–3] 2 [1–3] 2 [1–3] 2 [1–3] 2 [1–3] 0.36
VAS global Day 1 (%)
 N 331 159 351 1414 3736
 <20 17 18 16 16 30 0.53
 20‑49 32 28 33 26 28
 ≥50 51 55 51 58 42
 Median [p25‑75] 50 [28–71] 52 [25–73] 50 [28–68] 55 [30–75] 40 [15–66] 0.72
VAS global – all days (%)
 N days 3186 2594 4093 9780 23,377
 N users 507 256 548 2196 4569
 Average number of days 
per  user±
6.3 10.1 7.5 4.5 5.1
 <20 42 55 52 48 58 0.0001
 20‑49 32 27 30 28 24
 ≥50 26 18 18 24 18
 Median [p25‑75] 26 [8–50] 16 [6–38] 19 [7–39] 21 [7–48] 14 [3–38] 0.0001
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treatment and a longitudinal study was not feasible 
since users mostly use the App intermittently.
In the current study, we cannot ascertain that the 
users are allergic to a given allergen since this informa-
tion is not available for all patients. Moreover, we did 
not assess the real pollen exposure of the patients, as 
only 60% of them agreed to be geolocated.
The diagnosis of AR was not supported by a phy-
sician but was a response to the question: “Do you 
have allergic rhinitis? Yes/No”. Some of the users with 
Table 5 Results for all participants recruited outside the pollen season
FF Fluticasone Furoate, MF Mometasone Furoate, MPAzeFlu Azelastine-Fluticasone Propionate
* Comparing MPAzeFlu versus FF or MF. Chi square tests were used for categorical variables (i.e. symptoms and impact of symptoms, ARIA score, global VAS 
categories); Kruskal–Wallis tests were used for continuous variables (i.e. ARIA score, global VAS)
±  Estimated by dividing the total number of days for which the use of a medication was reported by the total number of users reporting that medication
p25: 25th percentile; p75: 75th percentile
N users Day 1 Treatment days No treatment days P value*
FF MPAzeFlu MF OAH mono
99 80 95 275 1299
Symptoms day 1
 Runny nose (%) 72 55 65 71 65 0.03
 Itchy nose (%) 72 53 61 61 53 0.03
 Sneezing (%) 76 49 71 74 67 <0.001
 Nasal congestion (%) 84 63 78 65 62 0.001
 Red eyes (%) 39 21 38 41 36 0.006
 Itchy eyes (%) 55 38 47 62 52 0.04
 Watery eyes (%) 41 29 27 45 34 0.35
Impact of symptoms day 1
 Sleep (%) 47 36 43 35 32 0.17
 Daily activities (%) 46 36 34 37 38 0.54
 Work/school (%) 30 31 24 25 24 0.51
 Bothersome (%) 84 55 68 67 67 <0.001
ARIA score (%)
 0 8 22 19 20 23
 1 30 38 29 34 31
 2 23 16 22 21 21 0.06
 3 22 10 22 12 15
 4 16 14 7 13 11
 Median [p25‑75] 2 [1–3] 1 [1–2] 2 [1–3] 1 [1–3] 1 [0–2] 0.04
VAS global day 1 (%)
 N 99 80 95 275 1299
 <20 25 29 27 27 41 0.68
 20‑49 28 34 33 31 29
 ≥50 46 38 40 42 30
 Median [p25‑75] 44 [19–67] 34.5 [15–62.5] 46 [17–64] 38 [18–66] 29 [6–54] 0.25
VAS global – all days (%)
 N days 1116 1258 1437 1956 13,120
 N users 167 128 154 437 1553
 Average number of days 
per  user±
6.7 9.8 9.3 4.5 8.5
 <20 50 54 59 50 74 0.0001
 20‑49 29 33 27 27 16
 ≥50 21 13 15 23 10
 Median [p25‑75] 19 [5.5‑44] 18 [7–36] 14 [5–34] 19 [5‑47] 5 [0‑20] 0.18
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non-allergic rhinitis may therefore have responded 
“Yes” to the question. However, > 95% of responders 
declared symptoms of AR by questionnaire. Precise 
patient characterization is impossible using an App, 
but every observational study using MASK was able 
to identify days with poor control or criteria of sever-
ity [26, 27, 30–32]. Moreover, some data are highly 
similar across studies. These include the percentage of 
Fig. 2 Proportion of INCS treatment groups on all days during and outside the pollen season
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untreated days (i.e. approximately 50% of the total days 
recorded).
There is a clear deviation in the results obtained in 
highly populated countries and a very high prevalence of 
allergic rhinitis with little collection data. These results 
could possibly influence the data.
The current study has many strengths including larger 
numbers, multiple countries, range of treatments studied 
and patient/person-generated data.
Interpretation of the results and generalizability
This real-world assessment of the Allergy Diary using 
VAS allows the  assessment of treatment efficacy by days 
[4, 11]. This observational study complements the two 
previous studies in many aspects (Table 7).
First, it shows that over 75% of patients using the app 
during the pollen season have bothersome symptoms. 
Outside of the pollen season, the rate of bothersome 
symptoms is around 65%. It is therefore likely that most 
App users have moderate/severe AR and do not therefore 
represent the general population [33]. It is interesting to 
note that these levels of impairment are close to those 
of patients consulting in primary [34] or specialist care 
[35]. Although the impact of AR is less important outside 
the pollen season than during, differences are not very 
important in the ARIA score.
Second, it was expected that MPAzeFlu would have 
been given to more severe patients. The ARIA score was 
not different between groups in the pollen season. In 
contradistinction, the ARIA score was significantly lower 
outside the pollen season in untreated users and even 
lower in the MPAzeFlu users.
Third, both during and outside the pollen season, 
MPAzeFlu is associated with less symptoms, something 
that seems consistent with being the most potent medi-
cation in a randomized controlled trial [36]. However, 
there are differences between seasons. During the pol-
len season, the use of MPAzeFlu is associated with the 
lowest VAS levels in treated groups, and MPAzeFlu is 
used more commonly as monotherapy. Outside of the 
pollen season, all medications appear to be associated 
with similar VAS levels. However, MPAzeFlu is used as 
a monotherapy in 70% of days whereas the other INCS 
are used in less than 50% of days. Nevertheless, given 
the cross-sectional setting of our study, effectiveness 
cannot be inferred easily.
Fourth, the estimated average number of days reported 
per user in the MPAzeFlu group was almost twice as 
high as that among the OAH group. Although there is no 
simple interpretation, it is suggested that the most effec-
tive treatments are reported for a longer period of time. 
However, we cannot assess duration in this cross-sec-
tional setting, but this finding is consistently found across 
MASK studies [11]. Again, there is no major difference 
between seasons.
Fifth, as already found in all users [4, 11], median VAS 
levels are the lowest in untreated days, both during and 
outside the pollen season. This can be interpreted as 
subjects using treatment when they do not feel well, in 
opposition to the paradigm in which those who take 
medication are the ones with controlled symptoms (and 
therefore lower VAS). Also, the patterns of co-medica-
tion of MPAzeFlu by comparison to FF or MF are similar 
in the two periods.
Table 6 New information provided by this paper
1. There was no differential assessment of MASK during and between the pollen seasons
2. There was  no assessment of baseline characteristics
3. Patients included in MASK have moderate/severe AR during and outside the pollen season although they were less severe outside the pollen season
Table 7 Key messages
1. What is already known about this topic? The MASK mHealth App has generated real‑world evidence that has led to novel pharmacotherapy insights 
– for example, that patterns of treatment for allergic rhinitis do not always accord with guidelines.
2. What does this article add to our knowledge?
Results can be extended to both the estimated pollen season and the period outside. The study shows that rhinitis medications are equally effective 
during and outside the pollen season.
The baseline characteristics of the patients show that most users have moderate to severe rhinitis and that mHealth data may not be generalisable to 
all patients with allergic rhinitis
3. How does this study impact current management guidelines?
This paper confirms the importance of the MASK mHealth App in next‑generation GRADE guidelines that embed real‑world‑evidence into the GRADE‑
based evidence.
The same treatment can be administered during and outside the pollen season
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Sixth, the behaviour of users appears to be quite simi-
lar between seasons. In particular, they report the same 
number of days with the same medications.
This study shows that, in real-life, the same treatments 
have similar patterns during and outside the pollen sea-
son for most criteria tested. This is an important find-
ing that may impact guidelines considering AR severity 
rather than seasonal patterns [37, 38].
Conclusions
Although the MASK mHealth App has generated real-
world evidence that has led to novel pharmacotherapy 
insights, the current study extends our knowledge by (i) 
assessing the characteristics of the patients, (ii) showing 
that results can be extended to both the estimated pollen 
season and the period outside the season, and (iii) show-
ing that rhinitis medications are equally effective during 
and outside the pollen season (Table 5).
Real-world data (RWD) and real-world evidence 
(RWE) both play an increasing role in health care deci-
sions supporting clinical trial designs and observa-
tional studies to generate innovative and new treatment 
approaches. This study shows that the overall efficacy of 
treatments is similar during and outside the pollen sea-
son and indicates that medications are similarly effective 
during the year. It is an important study for the digital 
transformation of health and care in rhinitis and asthma 
multimorbidity [3, 39–41].
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